CA2367355A1 - Produit medicinal destine au traitement du diabete - Google Patents

Produit medicinal destine au traitement du diabete Download PDF

Info

Publication number
CA2367355A1
CA2367355A1 CA002367355A CA2367355A CA2367355A1 CA 2367355 A1 CA2367355 A1 CA 2367355A1 CA 002367355 A CA002367355 A CA 002367355A CA 2367355 A CA2367355 A CA 2367355A CA 2367355 A1 CA2367355 A1 CA 2367355A1
Authority
CA
Canada
Prior art keywords
pancreatin
mixture
accordance
digestive enzymes
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002367355A
Other languages
English (en)
Other versions
CA2367355C (fr
Inventor
Suntje Sander-Struckmeier
Claus Rudolf Steinborn
Martin A. Rudmann
Diethard Schwanitz
Friederike Henniges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2367355A1 publication Critical patent/CA2367355A1/fr
Application granted granted Critical
Publication of CA2367355C publication Critical patent/CA2367355C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des mélanges d'enzymes physiologiquement acceptables ayant une action lipolytique, protéolytique et amylolytique d'origine microbienne ou animale, notamment des mélanges d'enzymes digestives, par exemple, de pancréatine ou de mélanges d'enzymes digestives contenant de la pancréatine. Ces mélanges sont utilisés pour le traitement du diabète et la production des médicaments convenant à ce traitement. Selon une variante, l'invention concerne l'utilisation de ces mélanges d'enzymes ayant une action lipolytique, protéolytique et amylolytique, notamment de pancréatine ou de mélanges d'enzymes digestives contenant de la pancréatine pour le traitement auxiliaire du diabète sucré de type I comme de type II.
CA2367355A 1999-03-17 2000-03-15 Produit medicinal destine au traitement du diabete Expired - Lifetime CA2367355C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19911778.0 1999-03-17
DE19911778 1999-03-17
PCT/EP2000/002261 WO2000054799A2 (fr) 1999-03-17 2000-03-15 Medicament destine au traitement du diabete

Publications (2)

Publication Number Publication Date
CA2367355A1 true CA2367355A1 (fr) 2000-09-21
CA2367355C CA2367355C (fr) 2012-06-05

Family

ID=7901217

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2367355A Expired - Lifetime CA2367355C (fr) 1999-03-17 2000-03-15 Produit medicinal destine au traitement du diabete

Country Status (23)

Country Link
US (1) US7122357B2 (fr)
EP (1) EP1162995B1 (fr)
JP (1) JP4938174B2 (fr)
CN (1) CN1221284C (fr)
AT (1) ATE242003T1 (fr)
AU (1) AU773930B2 (fr)
BR (1) BR0009012A (fr)
CA (1) CA2367355C (fr)
CZ (1) CZ20013345A3 (fr)
DE (2) DE50002450D1 (fr)
DK (1) DK1162995T3 (fr)
ES (1) ES2194720T3 (fr)
HK (1) HK1044477B (fr)
HU (1) HUP0200556A3 (fr)
NO (1) NO20014507L (fr)
NZ (1) NZ514826A (fr)
PL (1) PL199180B1 (fr)
PT (1) PT1162995E (fr)
RU (1) RU2268065C2 (fr)
SK (1) SK284677B6 (fr)
TR (1) TR200102784T2 (fr)
WO (1) WO2000054799A2 (fr)
ZA (1) ZA200107110B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7020384B1 (en) 1999-08-12 2006-03-28 Lg Electronics Inc. Method for creating and recording transport time information for data recorded on a disk
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US7519274B2 (en) 2003-12-08 2009-04-14 Divx, Inc. File format for multiple track digital data
DE602005009677D1 (de) 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
CA2586222A1 (fr) * 2004-05-24 2005-12-08 Novozymes A/S Enzymes a vocation pharmaceutique
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US8017351B2 (en) * 2005-06-24 2011-09-13 Novozymes A/S Amylases for pharmaceutical use
EP1896058A2 (fr) * 2005-06-24 2008-03-12 Novozymes A/S Protéases à usage pharmaceutique
AU2006261442A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Lipases for pharmaceutical use
WO2007014896A1 (fr) 2005-07-29 2007-02-08 Solvay Pharmaceuticals Gmbh Procédé de fabrication de poudre de pancréatine stérilisée
SI1931316T1 (sl) 2005-08-15 2010-06-30 Solvay Pharm Gmbh Farmacevtski sestavki z nadzorovanim sproščanjem za kislinsko labilna zdravila
MX2008001557A (es) * 2005-08-15 2008-02-15 Solvay Pharm Gmbh Nucleos de microglobulos de pancreativa adecuados para revestimiento enterico.
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
UA89102C2 (ru) * 2005-08-15 2009-12-25 Солвей Фармасьютикалс Гмбх Ядра микропеллета панреатита, пригодные для нанесеня энтеросолюбильного покрытия
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8071089B2 (en) * 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
KR20090101930A (ko) 2006-12-21 2009-09-29 노보자임스 에이/에스 약학적 사용을 위한 리파아제 변형체
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CA2707658A1 (fr) 2007-12-04 2009-06-11 Novozymes A/S Variants de protease pour une utilisation pharmaceutique
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
WO2010002972A1 (fr) 2008-07-01 2010-01-07 Curemark, Llc Procédés et compositions pour le traitement de symptômes de troubles de santé neurologiques et mentaux
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
NZ593823A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or the prevention of infections by e. coli
ES2668909T3 (es) 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
MX2012012794A (es) * 2010-05-03 2013-03-12 Aptalis Pharma Ltd Composiciones de microgranulos que comprenden pancreatina que contienen mezclas de enzimas digestivas.
MX347770B (es) 2011-04-21 2017-05-12 Curemark Llc Compuesto para el tratamiento de alteraciones neuropsiquiatricas.
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
WO2013155476A1 (fr) * 2012-04-12 2013-10-17 Integrative Enzymatics, Inc. Composition et procédé pour moduler des molécules inflammatoires avec l'amylase
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP3685661A4 (fr) * 2017-09-19 2021-05-19 Meiji University Procédé de développement d'organe dépourvu de cellule fonctionnelle spécifique
CN109142728A (zh) * 2018-09-04 2019-01-04 深圳市鸿美诊断技术有限公司 一种定量测定粪便中胰弹性蛋白酶1的试剂盒及其应用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803305A (en) * 1962-12-28 1974-04-09 Rolland A Lab Process for obtaining extracts from pancreas
DE2512746C3 (de) 1975-03-22 1980-04-24 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von keimarmem, faserfreiem Pankreatin
SU908352A1 (ru) * 1980-02-11 1982-02-28 Винницкий Областной Госпиталь Для Инвалидов Отечественной Войны Способ лечени гнойных ран
DE4203315A1 (de) 1991-02-14 1992-08-20 Kali Chemie Pharma Gmbh Verfahren zur gewinnung von pankreatin
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics

Also Published As

Publication number Publication date
HUP0200556A2 (en) 2002-06-29
JP4938174B2 (ja) 2012-05-23
AU4395000A (en) 2000-10-04
WO2000054799A2 (fr) 2000-09-21
PT1162995E (pt) 2003-08-29
US7122357B2 (en) 2006-10-17
DK1162995T3 (da) 2003-06-23
PL199180B1 (pl) 2008-08-29
US20020061302A1 (en) 2002-05-23
CA2367355C (fr) 2012-06-05
PL350627A1 (en) 2003-01-27
EP1162995A2 (fr) 2001-12-19
TR200102784T2 (tr) 2002-04-22
NZ514826A (en) 2003-08-29
SK12852001A3 (sk) 2002-02-05
ES2194720T3 (es) 2003-12-01
CN1221284C (zh) 2005-10-05
SK284677B6 (sk) 2005-09-08
NO20014507D0 (no) 2001-09-17
BR0009012A (pt) 2001-12-26
AU773930B2 (en) 2004-06-10
CZ20013345A3 (cs) 2002-01-16
DE10012095A1 (de) 2000-09-21
HUP0200556A3 (en) 2006-06-28
HK1044477B (zh) 2006-02-03
WO2000054799A3 (fr) 2001-04-26
ZA200107110B (en) 2002-10-30
CN1343126A (zh) 2002-04-03
EP1162995B1 (fr) 2003-06-04
HK1044477A1 (en) 2002-10-25
JP2002539173A (ja) 2002-11-19
RU2268065C2 (ru) 2006-01-20
DE50002450D1 (de) 2003-07-10
ATE242003T1 (de) 2003-06-15
NO20014507L (no) 2001-09-17

Similar Documents

Publication Publication Date Title
CA2367355A1 (fr) Produit medicinal destine au traitement du diabete
RU2001126526A (ru) Лекарственное средство, предназначенное для лечения диабета
JP2002539173A5 (fr)
RU2006145899A (ru) Ферменты для фармацевтического применения
US5614189A (en) Recombinantly produced lipases for therapeutical treatment
RU2007149045A (ru) Липазы для фармацевтического применения
HUP0500560A2 (hu) Mikróbás enzimek új keverékei
HUT67436A (en) Process to prepare novel hydroxamic acid and n-hydroxyurea derivatives and pharmaceutical compn.s contg. them
EP0742012A3 (fr) Composition pharmaceutique contenant une substance inhibant la production de HSP47
ATE263571T1 (de) Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
RU2008102738A (ru) Протеазы для фармацевтического применения
Fabbro et al. Human acid beta-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites
AU2002223666B2 (en) Use of enzymes obtained from ciliates as medicaments for promoting digestion
US5679344A (en) Glucosamine composition and method
WO2013047082A1 (fr) Enzyme de dégradation d'un peptide opioïde exogène
EP0387945B1 (fr) Composition pour le traitement de l'insuffisance exocrine du pancréas, et l'utilisation de ladite composition
MY118262A (en) Sulfonamide-substituted benzopyran derivatives, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them
HUP9902421A2 (hu) Nyálkahártya-viszkozitást optimalizáló és bélfunkciót stimuláló hatású készítmények
MY115619A (en) Sulfonamide-substituted fused 5-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
TR200101980T2 (tr) Arilalkanoil türevleri, bunların preparasyon işlemleri
Nadel Roles of mast cell proteases in airways
JPS61500431A (ja) 傷治癒に有用な活性化され、安定化された酵素
RU2068698C1 (ru) Лекарственное средство для лечения больных со сниженной внешнесекреторной функцией поджелудочной железы
EP0373335B1 (fr) Protéines inhibitrices des protéases du type sérine, médicaments les contenant, séquence d'ADN codant pour ces protéines et les procédés de production de ces protéines, médicament et séquences
US20020151481A1 (en) MMP-2 propeptide for use as antiangiogenic or antitumor agent

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200315